T-cell leukemia

[Neurotherapeutics] Individuals with HIV-associated amyotrophic lateral sclerosis (ALS) show a remarkable response to antiretroviral therapy; however, antiretroviral trials in ALS down-regulate HML-2 without ameliorating the disease.

[Twist Bioscience Corporation] Twist Bioscience Corporation and MediSix Therapeutics announced a collaboration to discover novel antibodies against five undisclosed targets. Twist will leverage its proprietary Library of Libraries to discover five novel antibodies directed against MediSix’s targets.

[Frontiers in Immunology] Investigators explored the impact of epigenetic modifiers and differentiation agents on leukemia cell lines of B cell origin, as well as normal B cells.

[Daiichi Sankyo Company, Limited] Daiichi Sankyo Company, Limited announced that it has submitted a New Drug Application to Japan’s Ministry of Health, Labour and Welfare for valemetostat, a potential first-in-class dual inhibitor of EZH1 and EZH2, for the treatment of patients with relapsed/refractory adult T cell leukemia/lymphoma.

[Cancer Science] The authors investigated the anti-adult T cell leukemia/lymphoma effects of a novel oral HSP90 inhibitor TAS-116 and the mechanisms involved in ex vivo and in vivo preclinical models.

[Blood] The authors performed whole-genome sequencing of 150 adult T cell leukemia/lymphoma (ATL) cases and revealed the overarching landscape of genetic alterations in ATL.